Core Viewpoint - The company has entered into a non-binding term sheet with PDC FZ-LLC for the exclusive licensing of its product Visepegenatide (PB-119), a GLP-1 receptor agonist for the treatment of type 2 diabetes and weight management, in the Middle East and Africa [1][2] Group 1: Licensing Agreement - The agreement grants PDC exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa [1] - The licensing includes regional development, product registration, local production involving comprehensive technology transfer, and exclusive commercialization rights [1] - The product will be marketed under a trademark owned by PDC in the specified regions [1] Group 2: Strategic Importance - This partnership is a significant milestone in the global commercialization strategy for PB-119, leveraging PDC's extensive regional expertise and infrastructure to accelerate market access and penetration [1][2] - The collaboration validates the company's asset output strategy and contributes significantly to the global positioning of the product and the long-term value creation for the company [1] Group 3: Market Potential - The Middle East and Africa represent a large and continuously growing market for diabetes and obesity treatment drugs, highlighting the unmet medical needs and commercial potential for innovative therapies like PB-119 [1] - The high prevalence and rising trends of these diseases underscore the importance of PB-119 in addressing significant healthcare demands in the region [1]
派格生物医药-B(02565)：建议授出VISEPEGENATIDE (PB-119) 于中东及非洲的独家许可